Reduction of early vein graft thrombosis by tissue plasminogen activator gene transfer

Thrombosis and Haemostasis

Volumn 102, Issue 1, 2009, Pages 145-152

  Thomas, Anita C ^a,b   Wyatt, Marcella J ^a   Newby, Andrew C ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Acute thrombosis; Animal model; Gene therapy; Tissue plasminogen activator; Vein graft

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD FLOW; CAROTID ARTERY; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY OBSTRUCTION; DISEASE SEVERITY; EX VIVO STUDY; GENE OVEREXPRESSION; GRAFT PERFUSION; LOCAL THERAPY; NONHUMAN; PRIORITY JOURNAL; SAPHENOUS VEIN; THROMBOSIS; VEIN GRAFT THROMBOSIS; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; BETA-GALACTOSIDASE; CAROTID ARTERIES; DISEASE MODELS, ANIMAL; GENE THERAPY; GRAFT OCCLUSION, VASCULAR; HUMANS; REGIONAL BLOOD FLOW; SAPHENOUS VEIN; SUS SCROFA; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR; TRANSDUCTION, GENETIC;

EID: 67749086360     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-11-0772     Document Type: Article

References (31)

1. Angelini GD, Newby AC. The future of saphenous vein as a coronary artery bypass conduit. Eur Heart J 1989; 10: 273-280.
2. Baker AH, Mehta D, George SJ, et al. Prevention of vein graft failure: potential applications for gene therapy. Cardiovasc Res 1997; 35: 442-450.
3. Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 1998; 97: 916-931.
4. White SJ, Newby AC. Gene therapy for all aspects of vein-graft disease. J Card Surg 2002; 17: 549-555.
5. Underwood MJ, Cooper G, More R, et al. Effect of intraluminal application of tissue-type plasminogen activator on the fibrinolytic activity of experimental vein grafts. Cardiovasc Res 1995; 29: 422-427.
6. Manchio JV, Gu J, Romar L, et al. Disruption of graft endothelium correlates with early failure after off-pump coronary artery bypass surgery. Ann Thorac Surg 2005; 79: 1991-1998.
7. Kauhanen P, Siren V, Carpen O, et al. Plasminogen activator inhibitor-1 in neointima of vein grafts: its role in reduced fibrinolytic potential and graft failure. Circulation 1997; 96: 1783-1789.
8. Poston RS, Gu J, Brown JM, et al. Endothelial injury and acquired aspirin resistance as promoters of regional thrombin formation and early vein graft failure after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2006; 131: 122-130.
9. Folts J. An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis. Circulation 1991; 83: IV3-14.
10. Folts JD. Drugs for the prevention of coronary thrombosis: From an animal model to clinical trials. Cardiovasc Drugs Ther 1995; 9: 31-43.
11. Strony J, Beaudoin A, Brands D, et al. Analysis of shear stress and hemodynamic factors in a model of coronary artery stenosis and thrombosis. Am J Physiol 1993; 265: H1787-H1796.
12. Anderson HV, Kirkeeide RL, Krishnaswami A, et al. Cyclic flow variations after coronary angioplasty in humans: clinical and angiographic characteristics and elimination with 7E3 monoclonal antiplatelet antibody. J Am Coll Cardiol 1994; 23: 1031-1037.
13. George SJ, Lloyd CT, Angelini GD, et al. Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. Circulation 2000; 101: 296-304.
14. Angelini GD, Bryan AJ, Williams HM, et al. Distention promotes platelet and leukocyte adhesion and reduces short-term patency in pig arteriovenous bypass grafts. J Thorac Cardiovasc Surg 1990; 99: 433-439.
15. Carmeliet P, Stassen JM, van Vlaenderen I, et al. Adenovirus-mediated transfer of tissue-type plasminogen activator augments thrombolysis in tissue-type plasminogen activator-deficient and plasminogen activator inhibitor-1-overexpressing mice. Blood 1997; 90: 1527-1534.
16. Wilkinson GW, Akrigg A. Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector. Nucleic Acids Res 1992; 20: 2233-2239.
17. Lee BY, Assadi C, Madden JL, et al. Hemodynamics of arterial stenosis. World J Surg 1978; 2: 621-627.
18. Golino P, Cirillo P, Calabro P, et al. Expression of exogenous tissue factor pathway inhibitor in vivo suppresses thrombus formation in injured rabbit carotid arteries. J Am Coll Cardiol 2001; 38: 569-576.
19. Emeis JJ, van den Eijnden-Schrauwen, van den Hoogen CM, et al. An endothelial storage granule for tissue-type plasminogen activator. J Cell Biol 1997; 139: 245-256.
20. Eckstein RW, Gregg DE, Pritchard W. The magnitude and time of development of the collateral circulation in occluded femoral, carotid and coronary arteries. Am J Physiol 1941; 132: 351-361.
21. Waugh JM, Kattash M, Li J, et al. Gene therapy to promote thromboresistance: local overexpression of tissue plasminogen activator to prevent arterial thrombosis in an in vivo rabbit model. Proc Natl Acad Sci USA 1999; 96: 1065-1070.
22. Kimura H, Sakata Y, Hamada H, et al. In vivo retention of endothelial cells adenovirally transduced with tissue-type plasminogen activator and seeded onto expanded polytetrafluoroethylene. J Vasc Surg 2000; 32: 353-363.
23. Siren V, Kauhanen P, Carpen O, et al. Urokinase, tissue-type plasminogen activator and plasminogen activator inhibitor-1 expression in severely stenosed and occluded vein grafts with thrombosis. Blood Coagul Fibrinolysis 2003; 14: 369-377.
24. Hilfiker PR, Waugh JM, Li-Hawkins JJ, et al. Enhancement of neointima formation with tissue-type plasminogen activator. J Vasc Surg 2001; 33: 821-828.
25. Jiang X, Liu X, Zhang K, et al. Experimental study of tissue-type plasminogen activator gene to prevent vein grafts stenosis. J Huazhong Univ Sci Technolog Med Sci 2006; 26: 314-316.
26. Burggraf D, Martens HK, Dichgans M, et al. Matrix metalloproteinase (MMP) induction and inhibition at different doses of recombinant tissue plasminogen activator following experimental stroke. Thromb Haemost 2007; 98: 963-969.
27. Torsney E, Mayr U, Zou Y, et al. Thrombosis and neointima formation in vein grafts are inhibited by locally applied aspirin through endothelial protection. Circ Res 2004; 94: 1466-1473.
28. Nassar T, Akkawi S, Shina A, et al. In vitro and in vivo effects of tPA and PAI-1 on blood vessel tone. Blood 2004; 103: 897-902.
29. Mutch NJ, Moir E, Robbie LA, et al. Localization and identification of thrombin and plasminogen activator activities in model human thrombi by in situ zymography. Thromb Haemost 2002; 88: 996-1002.
30. Davies MG, Klyachkin ML, Dalen H, et al. The integrity of experimental vein graft endothelium - implications on the etiology of early graft failure. Eur J Vasc Surg 1993; 7: 156-165.
31. Bourassa MG, Campeau L, Lesperance J, et al. Changes in grafts and coronary arteries after saphenous vein aortocoronary bypass surgery: results at repeat angiography. Circulation 1982; 65: 90-97.